| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antiretroviral-drug resistance among patients recently infected with HIV.
|
N Engl J Med
|
2002
|
9.70
|
|
2
|
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
|
Science
|
2010
|
9.61
|
|
3
|
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
|
N Engl J Med
|
2009
|
4.54
|
|
4
|
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.
|
J Infect Dis
|
2005
|
3.93
|
|
5
|
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
|
J Infect Dis
|
2011
|
3.86
|
|
6
|
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
|
Hepatology
|
2008
|
3.14
|
|
7
|
Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease.
|
J Infect Dis
|
2004
|
2.91
|
|
8
|
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.
|
J Infect Dis
|
2003
|
2.54
|
|
9
|
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.
|
J Infect Dis
|
2011
|
2.34
|
|
10
|
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes.
|
J Virol
|
2004
|
2.33
|
|
11
|
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
|
J Infect Dis
|
2011
|
2.26
|
|
12
|
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
|
J Infect Dis
|
2011
|
2.12
|
|
13
|
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.
|
Virology
|
2006
|
2.07
|
|
14
|
Incidence of HIV superinfection following primary infection.
|
JAMA
|
2004
|
1.92
|
|
15
|
Impaired replication capacity of acute/early viruses in persons who become HIV controllers.
|
J Virol
|
2010
|
1.80
|
|
16
|
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains.
|
J Virol
|
2005
|
1.77
|
|
17
|
A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients.
|
J Acquir Immune Defic Syndr
|
2007
|
1.76
|
|
18
|
HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load.
|
J Virol
|
2005
|
1.76
|
|
19
|
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
|
Ann Intern Med
|
2014
|
1.75
|
|
20
|
Transmission behaviors of recently HIV-infected men who have sex with men.
|
J Acquir Immune Defic Syndr
|
2006
|
1.73
|
|
21
|
Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection.
|
J Acquir Immune Defic Syndr
|
2006
|
1.66
|
|
22
|
Diagnostic discordance for hepatitis C virus infection in hemodialysis patients.
|
Am J Kidney Dis
|
2005
|
1.60
|
|
23
|
Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types.
|
J Acquir Immune Defic Syndr
|
2011
|
1.54
|
|
24
|
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.
|
Clin Infect Dis
|
2013
|
1.53
|
|
25
|
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
|
Pharmacogenet Genomics
|
2012
|
1.52
|
|
26
|
Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies.
|
AIDS Patient Care STDS
|
2008
|
1.45
|
|
27
|
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.
|
Clin Infect Dis
|
2011
|
1.40
|
|
28
|
Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578).
|
AIDS
|
2006
|
1.37
|
|
29
|
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
|
AIDS
|
2012
|
1.34
|
|
30
|
Hepatitis C virus and death risk in hemodialysis patients.
|
J Am Soc Nephrol
|
2007
|
1.26
|
|
31
|
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
|
J Infect Dis
|
2013
|
1.26
|
|
32
|
Molecular analysis of HIV strains from a cluster of worker infections in the adult film industry, Los Angeles 2004.
|
AIDS
|
2006
|
1.25
|
|
33
|
Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men.
|
J Acquir Immune Defic Syndr
|
2008
|
1.14
|
|
34
|
Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California.
|
AIDS Patient Care STDS
|
2011
|
1.08
|
|
35
|
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.
|
J Acquir Immune Defic Syndr
|
2014
|
1.06
|
|
36
|
Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.
|
AIDS Res Hum Retroviruses
|
2010
|
1.02
|
|
37
|
Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment.
|
Neuroimage Clin
|
2013
|
1.01
|
|
38
|
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
|
J Infect Dis
|
2012
|
0.99
|
|
39
|
Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men.
|
Sex Transm Dis
|
2007
|
0.98
|
|
40
|
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
|
AIDS
|
2010
|
0.98
|
|
41
|
Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners.
|
J Acquir Immune Defic Syndr
|
2006
|
0.97
|
|
42
|
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
|
J Infect Dis
|
2012
|
0.96
|
|
43
|
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
|
Pharmacogenet Genomics
|
2014
|
0.95
|
|
44
|
Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2004
|
0.94
|
|
45
|
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.
|
J Virol
|
2004
|
0.93
|
|
46
|
Virologic correlates of anti-CMV IgG levels in HIV-1-infected men.
|
J Infect Dis
|
2013
|
0.93
|
|
47
|
Platelet count is associated with plasma HIV type 1 RNA and disease progression.
|
AIDS Res Hum Retroviruses
|
2007
|
0.91
|
|
48
|
Longitudinal analysis of CD8 T-cell responses to HIV and hepatitis C virus in a cohort of co-infected haemophiliacs.
|
AIDS
|
2005
|
0.90
|
|
49
|
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance.
|
AIDS
|
2008
|
0.89
|
|
50
|
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.
|
Clin Infect Dis
|
2013
|
0.89
|
|
51
|
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.
|
Antivir Ther
|
2012
|
0.88
|
|
52
|
Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies.
|
J Neurovirol
|
2011
|
0.88
|
|
53
|
Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.
|
AIDS
|
2013
|
0.87
|
|
54
|
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy.
|
J Acquir Immune Defic Syndr
|
2015
|
0.87
|
|
55
|
Impact of randomized antiretroviral therapy initiation on glucose metabolism.
|
AIDS
|
2014
|
0.86
|
|
56
|
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination.
|
J Virol
|
2008
|
0.86
|
|
57
|
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.
|
AIDS
|
2013
|
0.85
|
|
58
|
Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization.
|
J Virol
|
2013
|
0.84
|
|
59
|
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
|
J Acquir Immune Defic Syndr
|
2014
|
0.84
|
|
60
|
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
|
Pharmacogenet Genomics
|
2015
|
0.84
|
|
61
|
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
|
J Infect Dis
|
2012
|
0.83
|
|
62
|
Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection.
|
AIDS
|
2016
|
0.82
|
|
63
|
Isolation and characterization of an infectious HIV type 1 molecular clone from a patient with primary infection.
|
AIDS Res Hum Retroviruses
|
2002
|
0.81
|
|
64
|
Primary human immunodeficiency virus type 1 infection.
|
Curr HIV/AIDS Rep
|
2005
|
0.81
|
|
65
|
Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART.
|
J Acquir Immune Defic Syndr
|
2016
|
0.81
|
|
66
|
Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.
|
J Acquir Immune Defic Syndr
|
2015
|
0.79
|
|
67
|
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
|
J Antimicrob Chemother
|
2014
|
0.79
|
|
68
|
Open-label, randomized, parallel-group controlled clinical trial of massage for treatment of depression in HIV-infected subjects.
|
J Altern Complement Med
|
2012
|
0.78
|
|
69
|
Hepatitis C infection in dialysis patients: a link to poor clinical outcome?
|
Int Urol Nephrol
|
2006
|
0.78
|
|
70
|
Newer antiretroviral agents and how to use them.
|
Curr HIV/AIDS Rep
|
2009
|
0.78
|
|
71
|
Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing.
|
AIDS Res Hum Retroviruses
|
2014
|
0.78
|
|
72
|
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.
|
AIDS
|
2006
|
0.78
|
|
73
|
Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents.
|
J Acquir Immune Defic Syndr
|
2012
|
0.77
|
|
74
|
Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
|
Expert Opin Pharmacother
|
2008
|
0.77
|
|
75
|
A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.
|
AIDS Behav
|
2015
|
0.76
|
|
76
|
Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.
|
Pharmacogenet Genomics
|
2015
|
0.76
|
|
77
|
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
78
|
Measuring below the bar: what is it telling us?
|
AIDS
|
2006
|
0.75
|
|
79
|
Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.
|
Pain Med
|
2013
|
0.75
|
|
80
|
Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.
|
Pharmacogenet Genomics
|
2017
|
0.75
|
|
81
|
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.
|
J Acquir Immune Defic Syndr
|
2010
|
0.75
|
|
82
|
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.
|
J Comp Eff Res
|
2015
|
0.75
|
|
83
|
Novel antiretroviral agents in HIV therapy.
|
Curr Infect Dis Rep
|
2006
|
0.75
|
|
84
|
What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2.
|
AIDS Read
|
2004
|
0.75
|
|
85
|
Strategies for initiating combination antiretroviral therapy.
|
AIDS Patient Care STDS
|
2005
|
0.75
|
|
86
|
Antiretroviral rounds. The when, why and how of switching.
|
AIDS Clin Care
|
2003
|
0.75
|
|
87
|
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
|
Ther Drug Monit
|
2017
|
0.75
|
|
88
|
Antiretroviral rounds. Putting resistance to work.
|
AIDS Clin Care
|
2004
|
0.75
|
|
89
|
What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1.
|
AIDS Read
|
2004
|
0.75
|
|
90
|
Newer antiretroviral agents and how to use them.
|
Curr Infect Dis Rep
|
2009
|
0.75
|